Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC

Phase 3 EVOKE-03/KEYNOTE-D46 reports numerically longer progression-free survival and higher response rates, but no statistically significant PFS or OS benefit SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a...